EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY 4.0

Prophylactic treatment of dacomitinib‐induced skin toxicities in epidermal growth factor receptor‐mutated non–small‐cell lung cancer: A multicenter, Phase II trial

Masahiro Iwasaku iD, Junji Uchino iD, Kenji Chibana, Shigeru Tanzawa, Takahiro Yamada, Kazunori Tobino, Yasuki Uchida iD, Takashi Kijima, Katsumi Nakatomi, Miiru Izumi, Nobuyo Tamiya, Hideharu Kimura und 7 weitere

Cancer Medicine · 2023

DOI: 10.1002/cam4.6184 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Cancer Medicine, 2023. Verfasst von Masahiro Iwasaku und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Dacomitinib significantly improves progression‐free survival and overall survival (OS) compared with gefitinib in patients with non–small‐cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR)‐activating mutations. However, dacomitinib often causes skin toxicities, resulting in treatment discontinuation. We aimed to evaluate a prophylactic strategy for skin toxicity induced by dacomitinib.

Methods

We performed a single‐arm, prospective, open‐label, multi‐institutional phase II trial for comprehensive skin toxicity prophylaxis. Patients with NSCLC harboring EGFR‐activating mutations were enrolled and received dacomitinib with comprehensive prophylaxis. The primary endpoint was the incidence of skin toxicity (Grade ≥2) in the initial 8 weeks.

Results

In total, 41 Japanese patients participated between May 2019 and April 2021 from 14 institutions (median age 70 years; range: 32–83 years), 20 were male, and 36 had a performance status of 0–1. Nineteen patients had exon 19 deletions and L858R mutation. More than 90% of patients were perfectly compliant with prophylactic minocycline administration. Skin toxicities (Grade ≥2) occurred in 43.9% of patients (90% confidence interval [CI], 31.2%–56.7%). The most frequent skin toxicity was acneiform rash in 11 patients (26.8%), followed by paronychia in five patients (12.2%). Due to skin toxicities, eight patients (19.5%) received reduced doses of dacomitinib. The median progression‐free survival was 6.8 months (95% CI, 4.0–8.6 months) and median OS was 21.6 months (95% CI, 17.0 months–not reached).

Conclusion

Although the prophylactic strategy was ineffective, the adherence to prophylactic medication was quite good. Patient education regarding prophylaxis is important and can lead to improved treatment continuity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansMaleAgedFemaleProspective StudiesProtein Kinase InhibitorsErbB ReceptorsMutationQuinazolinones

Stichwörter der Autor:innen

dacomitinibdermatitisnon-small-cell lung cancersteroidssunscreen

Substanzen

Protein Kinase InhibitorsErbB ReceptorsdacomitinibQuinazolinones

Autor:innen und Institutionen

  • Department of Pulmonary Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
  • Department of Respiratory Medicine, National Hospital Organization Okinawa National Hospital, Okinawa, Japan.
  • Division of Medical Oncology, Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan.
  • Department of Pulmonary Medicine, Matsushita Memorial Hospital, Osaka, Japan.
  • Department of Respiratory Medicine, Iizuka Hospital, Iizuka, Japan.
  • Division of Respiratory Medicine, Department of Internal Medicine, Shiga University of Medical Science, Japan.

ORCID-Profile: Masahiro Iwasaku, Junji Uchino, Yasuki Uchida, Tadaaki Yamada, Koichi Takayama

Förderung

  • Pfizer

Zitieren

APA

Iwasaku, M., Uchino, J., Chibana, K., Tanzawa, S., Yamada, T., Tobino, K., Uchida, Y., Kijima, T., Nakatomi, K., Izumi, M., Tamiya, N., Kimura, H., Fujita, M., Honda, R., Takumi, C., Yamada, T., Kaneko, Y., Kiyomi, F., & Takayama, K. (2023). Prophylactic treatment of dacomitinib‐induced skin toxicities in epidermal growth factor receptor‐mutated non–small‐cell lung cancer: A multicenter, Phase II trial. Cancer Medicine. https://doi.org/10.1002/cam4.6184

Vancouver

Iwasaku M, Uchino J, Chibana K, Tanzawa S, Yamada T, Tobino K, et al. Prophylactic treatment of dacomitinib‐induced skin toxicities in epidermal growth factor receptor‐mutated non–small‐cell lung cancer: A multicenter, Phase II trial. Cancer Medicine. 2023. doi:10.1002/cam4.6184

BibTeX
@article{Iwasaku2023,
  author = {Iwasaku, Masahiro and Uchino, Junji and Chibana, Kenji and Tanzawa, Shigeru and Yamada, Takahiro and Tobino, Kazunori and Uchida, Yasuki and Kijima, Takashi and Nakatomi, Katsumi and Izumi, Miiru and Tamiya, Nobuyo and Kimura, Hideharu and Fujita, Masaki and Honda, Ryoichi and Takumi, Chieko and Yamada, Tadaaki and Kaneko, Yoshiko and Kiyomi, Fumiaki and Takayama, Koichi},
  title = {Prophylactic treatment of dacomitinib‐induced skin toxicities in epidermal growth factor receptor‐mutated non–small‐cell lung cancer: A multicenter, Phase II trial},
  journal = {Cancer Medicine},
  year = {2023},
  doi = {10.1002/cam4.6184}
}
Kostenlos starten →